Intellia Therapeutics, Inc. (NTLA) is a Healthcare company in the Biotechnology industry with a 48% Caution Score. Key strengths include Debt/Equity (0.13). Areas to watch: Revenue Growth (-9.5%), Return on Equity (-56.3%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.
This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.
See how our AI analyzes NTLA fundamentals to generate buy/sell signals and Strong Buy Scores.
Our AI evaluates Intellia Therapeutics, Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Caution rating:
Key developments and data points that may impact Intellia Therapeutics, Inc.'s trajectory:
How Intellia Therapeutics, Inc. stacks up against comparable Healthcare companies on key metrics:
Every investment carries risk. Here are the specific risk factors our analysis identified for Intellia Therapeutics, Inc.:
Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.
A snapshot of Intellia Therapeutics, Inc.'s financial health based on the most recent filings:
Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.
Based on our AI-powered fundamental analysis, NTLA has a Strong Buy Score of 48%, earning a "Caution" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.
Intellia Therapeutics, Inc. currently shows fundamental weakness that warrants careful analysis. Key concerns: Revenue Growth (-9.5%), Return on Equity (-56.3%). Consider waiting for improved metrics before building a position.
Our AI analyzes Intellia Therapeutics, Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 48% score:
Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.
Technical traders can view real-time demand and supply zones for NTLA on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.
With NTLA currently trading at $12.11, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.
Subscribe to demand zone alerts to receive real-time notifications when NTLA reaches key technical levels.
Intellia Therapeutics, Inc. operates in the Healthcare sector, specifically in Biotechnology. Understanding earnings trends is crucial for forecasting NTLA's trajectory.
Current revenue growth of -9.5% trails the average company.
Visit our Earnings Calendar to track upcoming NTLA earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.
Our AI projects NTLA's trajectory based on current fundamentals and historical patterns. With a 48% Strong Buy Score, here's what the data suggests:
Cautious Outlook: Intellia Therapeutics, Inc.'s fundamentals suggest potential headwinds. Key issues: Revenue Growth (-9.5%). Consider waiting for improved metrics or a more attractive entry point before building a position.
For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.
Understanding valuation is critical for determining if NTLA is fairly priced. Here's the current snapshot:
Our AI weighs these metrics against growth rates and margin quality to determine if NTLA offers compelling risk-adjusted returns at current prices.
Here's why investors are bullish on Intellia Therapeutics, Inc.:
While these positives exist, investors should weigh them against the risks outlined in the bear case below.
Every investment carries risk. Here are potential concerns for NTLA investors:
The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.
NTLA Summary: Intellia Therapeutics, Inc. earns a 48% Caution Score based on AI analysis of fundamental data. Trading at $12.11 with a $1.69B market cap, the stock may face headwinds that warrant a cautious approach.
Bull Case: Debt/Equity (0.13)
Watch: Revenue Growth (-9.5%), Return on Equity (-56.3%)
For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free NTLA PDF report.
Deepen your understanding of the concepts used in this NTLA analysis:
Learn how to evaluate stocks using financial statements and key metrics.
Understanding P/E RatioWhat P/E ratio tells you about a stock's valuation and growth expectations.
Return on Equity (ROE)Why ROE matters for stock selection and how to interpret it.
Stock Valuation MethodsCompare DCF, P/E, and other approaches to value stocks like NTLA.
What Are Demand Zones?Find key support and resistance levels for NTLA and other stocks.
How to Read Earnings ReportsUnderstand earnings per share, revenue surprises, and guidance.
Latest SEC filings for NTLA explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.